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ment in 2007 compared to 2006 (39.81% vs.24.27%, p0.0002) and a non-significant
decline in 2008 (39.81% vs. 30.10%, p0.077). Non-Linear DID models showed that
MTM patients were more likely to meet the HbA1c criterion in 2007 (OR: 2.48, 95%
CI: 1.04-5.85, p0.038). Linear DID models for HbA1c showed a mean reduction of
0.54% (95% CI: 0.091%-0.98%, p0.018) for MTM patients. Among MTM patients,
rates of meeting HbA1c criterion in 2008 declined to baseline values.
CONCLUSIONS: Despite their greater complexity, optimal diabetes care signifi-
cantly improved among patients who were exposed to MTM. Drop in optimal
HbA1c control after discontinuation ofMTM exposure highlights the importance of
regular access to MTM services.
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OBJECTIVES:Tobacco control policies have focused on a combination of a variety of
initiatives such as monitoring, smoke-free public sites, cessation programmes,
health warnings, advertising bans and taxation. Smoking cessation treatments are
also recommended, as smokers who try to quit without help often fail in their
attempt.METHODS: TOSCA has been developed as an open or closed cohort semi-
Markov model, where current and former smokers may quit or relapse in their
smoking status over time. The impact of a tobacco policy on the quit rate is mod-
elled using the tobacco control scale (TCS) which has been shown to correlate with
quit ratios. Smoking prevalence, demographic inputs and mortality rates are de-
rived from published literature. The model predicts smoking prevalence, cumula-
tive smoking attributable deaths and morbidities over time (lung cancer, stroke,
coronary heart disease and chronic obstructive pulmonary disease). The impact of
tobacco control policies can be assessed over a 60 year horizon. RESULTS: Each one
point increase in TCS reduces smoking prevalence in both the open and closed
cohort model by 0.05% in absolute terms. This reduces cumulative smoking attrib-
utable mortality by 0.08% at 20 years and 0.13% at 60 years for lung cancer. Similar
results were obtained for stroke, COPD and CHD. For the UK this results in 10,069
and 8,908 fewer deaths in the open and closed cohort models respectively. Reduc-
tion in morbidities was slightly higher particularly for stroke where there was a
1.4% and 2.0% reduction in events at 20 and 60 years respectively. CONCLUSIONS:
Comprehensive smoking cessation policy is instrumental in reducing smoking
prevalence, mortality and morbidity. The TOSCAmodel can demonstrates the im-
pact of tobacco policy on smoking prevalence, mortality and morbidity for several
European countries.
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OBJECTIVES: The objective of this research was to examine differences in patterns
of statin prescribingbetween Northern Ireland and England both before and after
the introduction of the Quality and Outcomes Framework (QOF)METHODS:North-
ern Ireland practices were matched with practices in England, statin prescribing
data and QOF achievement scores (for the first year post-QOF) were obtained.
Crude prescribing data frommatched practicesweremanipulated to provide a data
set of Defined Daily Doses (DDDs)/1000 patients and cost/DDD/1000 patients for
each statin drug entity covering 1 year before and after the introduction of QOF.
QOF achievements were converted into percentage scores for matched practices.
Main outcome measure: Cost per defined daily dose (DDD) per 1,000 patients
RESULTS: Significantly less statins (DDD/1,000 patients) were dispensed in North-
ern Ireland comparedwith thematched region in England both before and after the
introduction of QOF (P 0.001). Significantly more statins, however, were dis-
pensed in both regions after the introduction of QOF. As a result of the introduction
of QOF, the cost/DDD/1000 patients rose by £13.17 in NI, but fell by £3.76 in the
matched region in England. CONCLUSIONS: Strategies should be considered to
educate prescribers on cost-effectiveness by increasing their awareness of the neg-
ative budgetary impact resulting from early adoption of new and expensive statins
and by encouraging generic prescribing.
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OBJECTIVES: In Ukraine cardiovascular diseases occupy a leading place in the
structure of death rate (25,9 %) and are one of most reasons of country depopula-
tion. From data of evidence-basedmedicine application of hypolipidemic prepara-
tions of statins in complex therapy of cardiovascular diseases and for the prophy-
laxis of their complications assists the decline of both common and cardiovascular
death rate. The aim of this research is a choice the optimal preparations from the
statins for the secondary prophylaxis of acute coronary syndrome on the basis of
cost-minimization analysis results in Ukraine. METHODS: Cost-minimization
analysis of hypolipidemic therapy with statins for the secondary prophylaxis of
acute coronary syndrome. The objects are results of a fewmeta-analyses andmul-
ticentral clinical trials: STELLAR, MERCURY, GREACE, 4S (Scandinavian Simvasta-
tin Survival Study); preparations of statins presented at the pharmaceuticalmarket
of Ukraine. The prices on preparations were taken from the price-lists (October,
2010). RESULTS: The analysis of meta-analyses and multicentral clinical trials re-
sults of atorvastatin, simvastatin and rosuvastatin preparations showed that these
preparations have practically equal clinical effectiveness for the secondary pro-
phylaxis of acute coronary syndrome. The results of cost-minimization analysis
showed that the costs for preparations of atorvastatin were less than the costs for
preparations of simvastatin and rosuvastatin. The hypolipidemic therapy with
rosuvastatin are the most expensive. The costs for the course of prophylaxis by
preparations of simvastatin are less, than the costs for the course of prophylaxis by
rosuvastatin and more, than the costs for prophylaxis by atorvastatin.
CONCLUSIONS: Generic preparations of atorvastatin are the least expense among
others statins presented at the pharmaceutical market of Ukraine, and remain
preparations of choice for the prophylaxis of acute coronary syndrome.
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OBJECTIVES: To assess the impact of receiving emotional support on self-per-
ceived current health status and physical and mental health wellness among
adults with cardiovascular disorders (CVD) in the United States. METHODS: We
identified adults aged 40 years with CVD (i.e., self-reported stroke, congestive
heart failure, coronary heart disease or heart attack) in the 2007-2008 National
Health and Nutrition Examination Survey (NHANES), a nationally representative
survey of the non-institutionalized US population. Outcome measures including
self-reported current health status (poor [fair/poor] vs. good [good/very good/ex-
cellent]), days with poor physical health, days with poor mental health, and inac-
tive days due to poor physical/mental health, were compared between CVD pa-
tients receiving and not receiving emotional support using appropriate univariate
tests. All analyses were stratified by patient demographics, including gender and
race. National estimates were obtained using sample weights. RESULTS: In 2007-
2008, 12.4% (Population Estimate16.6 million; 95% CI: 14.2-19.0 million) of the US
population40 years of age had self-reported CVD, of which92% denoted having
someone (e.g., spouse, neighbor) provide emotional support, with the proportion
greater among females thanmales (93.7% vs. 89.8%; P0.188). Among CVD patients
not receiving emotional support, a greater proportion reported current health sta-
tus as ‘poor’ compared with patients receiving emotional support (51.2% vs. 34.6%;
P0.091). Similarly, compared with CVD patients receiving emotional support, the
number of dayswith poor physical health (6.9 vs. 12.3 days; P0.014),mental health
(4.4 vs. 7.8 days; P0.137), and inactive days (4.4 vs. 9.5 days; P0.101) were each2
times greater among patients not receiving emotional support. CONCLUSIONS: A
majority patients with CVD diagnosis reported receiving some emotional support,
with receipt of emotional support being associated with improved health status.
Health care providers (e.g., physicians, pharmacists) should emphasize the value of
emotional support to patientswith CVD,whichmay help in improving the physical
and mental well-being of these patients.
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OBJECTIVES: The objective of this study is to assess scope and role of drug thera-
pies in cardiology/vascular diseases in AOTM works. AOTM is one of a light touch
HTA Agencies around the world with respect to drugs evaluation before desion-
taking on reimbursement and pricing. AOTM stands for quality assurance of HTA
reports developed by industry applying for inclusion of drugs to BBP (basic benefit
package). It deals also with appraisal of submitted evidence. AOTM does not de-
velop HTA reports from the scratch with respect to drugs. Therefore no priority
setting process is needed and no bias in selection of topics for assessment should
be in place.METHODS:Among recommendations of AOTMpublished until the end
of 2011 we analyzed all related to cardiovascular drugs. RESULTS: Among 400
AOTM decisions verified only 31 (8%) were related to cardiovascular drugs. Recom-
mendation regarding non–drug technologies were issued to 47 (12%) of 400 tech-
nologies. 58 (15%) applied to drugs used in the treatment of nervous disorders, 34
(9%) metabolic disorders, 21 (5%) genito-urinary system. The largest number (142/
36% of 400) of analyzed submission was connected with antineoplastic and immu-
nomodulating agents; 105 (74%) of them regarding oncology treatment. Fifteen
percent of verified docummentations applied to other, single indications.
CONCLUSIONS: The influence of cardiovascular drugs for AOTM recommendations
were not significant and no bias with respect to special focus on cardiovascular drugs
has been observed in comparision to focus on other medicines. Most of commissions
prepared by AOTM were related to antineoplastic (cancer chemotherapy) treatment
representing normal trends in research and development in medicine.
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OBJECTIVES: Antihypertensive medication and lifestyle modification are crucial
for adequate control of hypertension in the vast majority of patients with this
condition. Poor adherence to one or both of these treatment modalities, however,
oftentimes prevents achievement of goal blood pressure. The primary objective of
this studywas to examine predictors of receiving and adhering to antihypertensive
medication and lifestyle modification for the treatment of hypertension.
METHODS: This study included adult respondents from the 2009 Behavioral Risk
Factor Surveillance Systemwho reported being diagnosed by a health care provider
as having hypertension (n38,474). A multivariable logistic regression model was
estimated to identify independent predictors of receiving and taking antihyperten-
sive medications as prescribed, as well as receiving and adhering to a lifestyle
modification advise from a healthcare provider, including modification of eating
habits, physical exercise, reduction of alcohol consumption and salt intake. The
following potential predictors were examined: respondent’s sex, education, em-
ployment,marital status, health status, health insurance access, cigarette use, and
geographic location. RESULTS: Black and older (65 years) patients were more
likely to be advised by healthcare providers to take medications for manage-
ment of their hypertension compared to White and younger patients (O.R.1.71
and OR11.2, p0.003 and p0.0001 respectively). All minority patients (Black,
Native Americans, Asians, and Hispanics) were more likely to receive a recom-
mendation about low-sodium diet and reduction of alcohol consumption com-
pared to Whites (p0.001). With respect to adherence to medication manage-
ment and life-style modifications, minority patients appeared to be similar or
even more adherent than White patients after controlling for respondent
characteristics. CONCLUSIONS: Our results indicate demographic differences
with regards to adherence to therapeutic medication and lifestyle-modification for
treating hypertension which may, in part, be a consequence of differences in how
providers counsel and treat patients based on their socio-demographic character-
istics.
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OBJECTIVES: Risk of cardiovascular disease death is 2-4 times higher in diabetics
than non-diabetics, and control of hypertension reduces this risk by up to 50%.
While there are numerous drug classes available for hypertension treatment, the
American Diabetes Association (ADA) specifically recommends ACE inhibitors or
ARBs because they offer additional vascular benefits in diabetes. Further, the ADA
suggests that multi-drug therapy is usually required to achieve blood pressure
targets. The objective of this study is to examine the prescribing patterns of anti-
hypertensive medications among diabetics relative the ADA recommendations.
METHODS:Data from the 2008 National AmbulatoryMedical Care Survey (NAMCS)
was utilized to identify office visits involving diabetic patients. This nationally
representative sample of US physician-patient office visits utilizes a multi-staged
sampling technique to collect several demographic and clinical parameters on
patient visits as well as information on up to eight continuous or newly prescribed
medications. Diabetes was identified by a physician questionnaire regarding pres-
ence of patient comorbidities and medications were identified using US National
Drug Codes. RESULTS: Of the 28,741 office visits collected, 2,955 were among dia-
betic patients and 49.3% (n1,456) of the diabetic patients were prescribed at least
one antihypertensive medication. ACE inhibitors were the most frequently pre-
scribed (40.9%), followed by beta blockers (39.4%), diuretics (30.2%), and calcium
channel blockers (20.5%). ARBs were less frequently prescribed (20%). Over half
(51.9%) were prescribed 2 or more hypertensive medications. CONCLUSIONS:
Based on data from the National Ambulatory Medical Care Survey, it appears that
ADA recommendations for hypertensive therapy in diabetics are being followed
with regard to ACE inhibitors and polytherapy. ARBs, however, appear less com-
mon in the population with other antihypertensive classes being prescribed more
frequently. Future studies involving longitudinal data are needed to evaluate
trending in the adherence to ADA recommendations for hypertensive therapy.
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OBJECTIVES: Readmission rates in the US following acute myocardial infarction
(AMI) remain high despite intensive medical therapy. This study evaluated the
association between antiplatelet therapy, aspirin  clopidogrel and the short and
long term readmission rates in patients whowere hospitalized for AMI.METHODS:
Patients with an index hospitalization for AMI in 2007–2009 and also received in-
hospital aspirin  clopidogrel were selected based on diagnoses and pharmacy
records from 122 hospitals in a US electronic medical record database (Cerner’s
Health Facts). Readmission for any reason or recurrent AMI within 30 days and 1
year following index AMI discharge was assessed based on hospital records. Mul-
tivariate logistic regressionwas used to estimate the association between readmis-
sion and in-hospital antiplatelet therapy, adjusted for age, gender, comorbidities,
AMI type, and coronary revascularization during index hospitalization. RESULTS:
Among 23,394 patients diagnosedwithAMI during index hospitalization (mean age
68.7 years; 58%male), 35% received aspirin alone and 65% received aspirin clopi-
dogrel in hospital. Patients on aspirin clopidogrel were younger, hadmore STEMI
diagnosis, higher rates for hypertension, dyslipidemia, diabetes, and PCI/stent
placement, but lower rates for atrial fibrillation, congestive heart failure, and cere-
brovascular disease than patients on aspirin alone (all p0.001). Patients who re-
ceived aspirin  clopidogrel had lower rates of readmission for any reason at 30
days (11.5% vs. 14.7%; adjusted odds ratio (OR)  0.89 [95% CI: 0.82, 0.97]) and at 1
year (33.2% vs. 37.3%; OR 1.06 [1.00, 1.13]) compared to aspirin alone. AMI-related
readmission rates were similar between in-hospital treatment regimens.
CONCLUSIONS: Both 30-day and 1-year readmission rates remain high post AMI
discharge, despite antiplatelet therapy using aspirin clopidogrel. In-hospital dual
antiplatelet therapy was associated with a reduction in short-term readmission
rate overall but not for long-term or recurrent AMI in this cohort.
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OBJECTIVES: To determine 30-day readmissions in patients with heart failure in
Arizona and to assess the association of sociodemographic characteristics, primary
payer, and case-mix risk adjustment with hospital readmissions. METHODS: The
2005 Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and
Utilization Project (HCUP) State Inpatient Database (SID) for Arizona was used. The
HCUP revisit files were utilized to identify 30-day same diagnosis-related group
(DRG) readmissions for heart failure and shock (DRG 127). Hospital dischargeswere
included if age 65 years with patient residence in Arizona, and excluded if a
diagnosis was missing or was for end stage renal disease (ESRD). Index events to
determine readmissions were identified if there was no DRG for heart failure and
shock in the 30-days prior to admission. Readmissions were reported at both pa-
tient-level and index-event level. The association of sociodemographic, primary
payer, and case-mix risk adjustment (i.e., Charlson index) on patient level hospital
readmissions were evaluated using multivariate logistic regression. RESULTS: In
2005, some 7828 discharges among 6688 patients were included in the analysis. A
total of 6,333 discharges qualified as index events. Patients were, on average,
79.9(7.9) yearswith a Charlson index of 2.6(1.4). Themajoritywerewhite (83.5%)
and female (53.0%). Inpatient mortality was 3.1%(n210). Mean discharges were
1.2(0.5) per patient and ranged from 1-7. The proportion of patients with at least
one readmission was 5.3% (n355) and 5.6% (n355) of 6,333 index events resulted
in a readmission. From the multivariate regression, only the Charlson index was
significantly associated with patients with 1 readmission (OR1.3; 95%CI: 1.3,
1.4). CONCLUSIONS: This investigation of hospital readmissions for heart failure
suggests that case-mix risk adjustment is a significant predictor of 30-day readmis-
sion. To better understand the influence of index events future analysis will con-
sider predictors of readmissions with an index event level analysis.
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OBJECTIVES: This survey investigated the implementation of hospital guidelines
for VTE prevention and protocols for VTE management/risk assessment and
thromboprophylaxis in hospitalized non-surgical, acutely-ill medical patients as
recommended by the American College of Chest Physicians.METHODS: As part of
a study of VTE in medically ill patients, identified from the HealthCore Integrated
Research Database, involving a random sample of 504 patients with medical
charts, a telephone survey of the 275 facilities in which these patients were hospi-
talizedwas conducted between June and September, 2011. An attemptwasmade to
contact Quality Management/Improvement (QM) coordinators at targeted institu-
tions. The survey consisted of a brief questionnaire (14 closed and 3 open-ended
questions) regarding the presence of hospital guidelines and risk assessment pro-
tocols. Results were summarized descriptively. RESULTS:We reached out to hos-
pital operators at all 275 facilities. Many of contacted persons, however, had diffi-
culty in identifying the QM department. Even when the correct department was
reached, approximately 90% of calls were routed directly to voicemail and repeated
calls (up to 3 calls at different times/days of week) were not returned.Wewere able
to directly speak with 30 (11%) QM coordinators, of whom, only 8 (27%) completed
the survey; 7 by telephone and 1 by email. Of the 8 (3%) hospitals that provided
responses, 76% had VTE-specific clinical guidance in place. Our low survey yield of
2.9% (8/275) is comparable with the response rate of 1.45% (21/1448) responding to
pertinent supplementary questions on VTE prevention in non-surgical patients
that were included in the survey conducted by the Joint Commission on Accredi-
tation for Healthcare Organizations (JCAHO) in 2009. CONCLUSIONS: QM depart-
ments in these hospitals are often unknown to hospital operators and QM coordi-
nators are generally hard to reach. Opportunities for improvement in the
implementation of VTE prophylaxis guidelines for hospitalized medically-ill pa-
tients exist.
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OBJECTIVES: To identify patient characteristics associated with filling a thien-
opyridine prescription (clopidogrel or prasugrel) following acute coronary syn-
drome (ACS) and percutaneous coronary intervention (PCI) in US health plans.
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